A Growing Pipeline

We are working on the discovery and early development of potential Adnectin therapeutics across a range of disease types.

Our research strategy is to create differentiated Adnectin-based compound candidates that meet areas of important unmet medical need. Working with our colleagues in the broader Bristol-Myers Squibb organization, we pursue the discovery and development of targets which meet the following criteria:

  • high degree of confidence in the biological pathway intervention point
  • potential for clinically meaningful differentiation versus existing treatments

Adnectins may be broadly applicable to a wide range of targets, creating an opportunity to study potentially differentiated compounds across many therapeutic areas.

Our first Adnectin clinical candidate, CT-322, is an anti-angiogenesis agent designed to block the VEGFR-2 pathway. In Phase 1, CT-322 showed evidence indicative of biological activity on the VEGFR-2 pathway1. CT-322 is currently in Phase 2 clinical trials in the United States.

In addition to CT-322, we are studying potential Adnectin therapeutics for study across a range of disease types, including oncology, immunology, and cardiovascular disease.

1. Clin Cancer Res. 2011 Jan 15;17(2):363-71. Epub 2011 Jan 11. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M.